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Abstract: From our prior studies concerning eugenol’s biologic activity we observed the very good in vitro antifungal efficiency of
this natural compound. Those positive results generated the need to supplement the available information with a comparative in vivo
animal model. In this context, our current study was proposed to ascertain and compare the effects of eugenol with nystatin with a
placebo control group (saline solution) by evaluating the cytohistological alterations in immunosuppressed Wistar female rats genitally
infected with Candida albicans. The observed histological alterations were most apparent in the placebo group. Candidiasis affected
the liver, ovaries, kidneys, and spleen of the infected female rats. When compared to the groups treated with eugenol and nystatin,
these alterations were either less discernible or were not reported at all, except for the liver degenerations, which were attributed to
the immunosuppressive activity of drugs used and not to the Candida infection. The efficiency in the in vivo experimental candidiasis
exerted by eugenol upon the tissues’ histoarchitecture allows us to seriously consider it as a promising antifungal active substance, useful
therapeutically in genital candidiasis and, in our opinion, with comparable biologic activity to that of nystatin.
Key words: Candida albicans, eugenol, genital infection, female rat model

1. Introduction
Although the range of Candida albicans infections
is generally considered to be well known, its various
manifestations are still commonly reported both in
animals and humans and are studied by many researchers.
Candidiasis infections still remain, to this day, a problem to
be dealt with (Henriques-Contente, 2004; Marlete, 2005).
Since fungal infections can have strong and extensive
action and at the same time be highly resistant to treatment,
candidiasis remains a current topic because of its medical
importance, frequency, and recurrence of emerging
infections. For example, vulvovaginal candidiasis is a
fungal infection that affects, even today, about a third of
all women at least once in their life. Approximately 5% of
these women are subject to recurrent episodes of vaginal
* Correspondence: rtcristina@yahoo.com

candidiasis (Fidel and Sobel, 1996; Fındık and Tuncer,
2002).
This fungal infection is often associated with other
conditions such as diabetes, treatments with antibiotics or
corticosteroids, pregnancy, and resistance to antifungals
(Dupont et al., 1996; Hata et al., 1996; Heseltine et al.,
2003; Jin and Lin, 2005; Jadhav and Pal., 2006), and many
treatment strategies and new antifungal agents are being
developed against this mycosis (Jones et al., 1976; Ghaly,
2009; Hanafi et al., 2010).
These results generated the need to supplement the
existing information with an animal model experiment.
In this context, we deemed necessary the development of
candidiasis in laboratory animals, as a preface for studies
aiming to confirm or refute the effectiveness of different
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regimens of eugenol. In this respect, our study proposes to
compare the effects of eugenol with a classic compound,
namely nystatin, and a placebo (saline solution) control
group, by evaluating the cytohistological organ alterations
in immunosuppressed Wistar female rats genitally infected
with Candida albicans.
2. Materials and methods
Research was performed in compliance with good
laboratory practice; in accordance with the European
Convention principles for the protection of vertebrate
animals used in experimental and other scientific purposes,
adopted in 1986 in Strasbourg (ECPVAEOSP, 1986), and
the 2010/63/EU Directive of the European Parliament
and of the European Council adopted 22 September
2010 on the protection of animals used for scientific
purposes (European Parliament, 2010); in accordance
with Romanian law for animal experimentation; and with
the acceptance of the Scientific Ethics Committee of the
Faculty of Veterinary Medicine of Timisoara (Romanian
Government, 2002). Euthanasia of rats respected the
procedures advocated by SVH AEC SOP.26 (Peirce, 2006).
2.1. Animals
The study involved 27 healthy young Wistar female rats
(divided into three, with experimental and negative
control groups), aged between 39 and 41 days, purchased
from the authorized biobase of the University of Medicine
and Pharmacy “Victor Babeş”, Timișoara. All females were
in the peripubertal period and of approximately the same
weight (average weight: 190 ± 10 g). The groups were kept
in facilities especially built for this purpose, in cages with
controlled temperature and light cycles (22 °C, light cycle
of 12 h starting at 0800 hours), with access to food and
water ad libitum.
2.2. Immunosuppression and genital infection scheme
To assist in the rapid progress of Candida albicans
infection, immunosuppressed female rats were used for
the study, according to the protocols developed by Sobel et
al. (1985) and improved by Chami et al. (2004).
To induce immunosuppression, all female rats from
the experiment were initially treated with dexamethasone
(Dex) (Cortamethasone, Vetoquinol), and a 4% tetracycline
soluble powder (Tc) (Laprophan) was also administered.
All rat females were immunosuppressed for a week-long
preinfection period. All rats were given 0.5 mg/L of Dex
and Tc (0.1%) via drinking water.
During the infection period, the dose of Dex was
increased to 1 mg/L while the Tc concentration was
reduced to 0.01%, which was maintained throughout the
experiment.
All female rats were infected genitally twice at intervals
of 24 h (days 0 and 1), with 0.1 mL of saline suspension that
contained 3.1 × 103 (3108 viable cells) Candida albicans,
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strain ATCC 10231, provided from the fungi collection of
the Department of Mycology of the Faculty of Veterinary
Medicine, Timișoara.
2.3. Antifungal assay scheme
For comparative efficacy testing, natural eugenol was used
(≥98%, FG) (C10H12O2) along with nystatin (C47H75NO17)
(syn., Fungicidin, Mycostatin) (N4014, Sigma Nystatin),
purchased from Sigma Aldrich (Germany). The
experimental series consisted of three groups composed of
fifteen rat females each:
•

ICAE: Immunosuppressed females infected with C.
albicans and treated with eugenol (nine female rats);

•

ICAN: Immunosuppressed females infected with C.
albicans and treated with nystatin (nine female rats);

ICA: Immunosuppressed females infected with C.
albicans and subjected to a placebo (saline solution),
used as a negative control group (nine female rats).
The rats were infected on day 0 and day 1 of the
experiment and treated over a 7-day period per group. Rats
(three from each group/day) were euthanized successively
at days 3, 6, and 9 after infection and fresh tissue samples
were collected in order to carry out the comparative
cytohistological investigation. Eugenol, nystatin, and
saline solution administrations were done orally, diluted
in 0.8% agar solution (CLSI, 2009), with syringe, twice a
day for 8 days as follows:
•

•

The ICAE group received 0.5 mL (~4 mg/animal).

•

The ICAN group received a suspension of 0.5 ml
(~0.054 mg/animal).

•

The ICA group received saline solution at 0.5 mL/
animal.
The entire experimental process is presented
schematically in Figure 1.
2.4. Sample collections and cytohistological technique
The main cytohistological alterations were identified
mainly in the following organs: liver, spleen, kidneys,
and ovaries. For the intestines, lungs, uterus, and nervous
system, changes were not relevant to this study. Fresh tissue
fragments for the cytohistological investigation were fixed
in 80% alcohol for 7 days, after which they were washed,
dehydrated, and embedded in paraffin.
Paraffin blocks including fragments of tissue were
sectioned using a microtome, yielding sections of 5 µm in
thickness, after which they were mounted on glass slides
with Mayer albumin following the technique described by
Șincai (1996). The coloration was the classical hematoxylin
eosin (H&E) and microscopy was performed at 200× and
400× magnifications, the images being processed with an
Olympus CX 41 microscope with image capture software
and data interpretation.
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Figure 1. Scheme of the experimental design.

3. Results
The results after treatments with eugenol were compared
to those obtained following the administration of
nystatin. The alterations observed resulting from
immunosuppression and infection were reduced to
moderate at the beginning phase of the experiment (days
3 and 6) and were eventually eliminated, according to our
following analysis on day 9 of the study, probably due to
the studied rats’ healing resources.
The main histologic changes were observed on days 3
and 6, as presented in Figure 2. For the immunosuppressed
infected females that were treated with eugenol and
nystatin, the results were quite similar and did not indicate
any major changes in organ histology; only representative
histoarchitecture changes are presented.
3.1. Ovary
The histological analysis performed on ovaries (Figure 2A)
sampled from the immunosuppressed, infected rat females
treated with placebo revealed oocytes and degenerative
lesions, accompanied by ovarian follicular edema in the
cortical zone. For females that were treated with eugenol
(Figure 2B) and nystatin, ovarian follicular edema in
the cortical zone was observed. The similarity between
the results from the experimental ICAE and ICAN
groups can most likely be accredited as a result of the
immunosuppression phenomenon and the degeneration
of interstitial cells responsible for the secretion of sexual
hormones in all groups.
3.2. Liver
In the liver (Figures 2C and 2D), on days 3 and 6, degenerative
processes of the hepatocytes could be observed, together
with hydropic dystrophy, karyopyknosis, and karyolysis,
which affected the liver function and its cellular integrity
in the immunosuppressed infected animals that were
treated with eugenol or nystatin. These changes were more
evident in the placebo group.

This reaction could be attributed to the hepatic
immunosuppressive drugs in the case of the experimental
groups treated with eugenol or nystatin. These alterations,
however, manifested only for a short period of time and
were not present after the sixth day of treatment, when
the cytoplasmic and nuclear structure of hepatocytes had
returned to normal as a consequence of the regenerative
healing, an observation justified by the return to normal
cytoplasmic and nuclear structure of hepatocytes and thus
the liver’s refunctionalizing.
These observations, although not backed by laboratory
tests, show that although infection with Candida albicans
causes a major effect on the liver within 6 days, this organ
has remarkable regenerative capacity, as in our case after
the sixth day and especially in the case of the eugenol
group.
3.3. Kidneys (fig. 2 E-F)
After 3 days, in the immunosuppressed infected animals
that were treated with placebo (Figure 2E), the emergence
of large zones of degenerative phenomena was observed,
manifested mainly by tumescence of convoluted tubule
nephrocytes and Bowman’s capsule destruction, followed
by the disappearance of uriniferous spaces. This can
lead to glomerulonephritis, the alterations being found
irreversible after days 6 and 9. We observed that in the
case of the immunosuppressed, infected specimens that
were treated with eugenol or nystatin (Figure 2F), these
alterations were much more reduced in intensity and
extent.
3.4. Spleen
A dramatic reduction of the areas of leucopoiesis could be
observed (Figures 2G and 2H). This had a major effect on
the formation of white blood cells, but the erythropoiesis
areas remained unchanged. It is also worth mentioning
that spleen lymph nodes remained present in the form of
lymphocyte cords, the C. albicans infection blocking the

457

CRISTINA et al. / Turk J Biol

Figure 2. The main observed histologic changes in immunosuppressed female rats infected with C. albicans. A) Ovary from placebo
group: degenerative lesions of oocytes [a], ovarian follicular edema [b] in the cortical zone, H&E 200×. B) Ovary from eugenol group:
edema of ovarian follicles [a] in the cortical region, H&E 400×. C) Liver from placebo group: degenerative process of hepatocytes,
degenerative process of hepatocytes, hydropic dystrophy [a], karyolysis and karyopyknosis [b], H&E, 400×. D) Liver from eugenol
group: normal structure at 6 days, H&E, 200×. E) Kidney from placebo group: extensive degenerative phenomena manifested by
tumescent nephrocytes of the distal and proximal tubule [a] and destruction of Bowman’s capsule [b], H&E 400×. F) Kidney from
eugenol group: extensive degenerative phenomena manifested by slightly tumescent nephrocytes of the distal and proximal tubules [a],
H&E 400×. G) Spleen from placebo group: dramatic reduction of the first phase areas of leucopoiesis [a], splenic lymph nodes remain
or are present only in the form of cord lymphocytes [b], H&E, 200×. H) Spleen from eugenol group: reduction in the first-phase areas
of leucopoiesis [a], H&E, 400×.
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progress of reactivity and proliferation of leukocytes, as is
known in infectious diseases.
4. Discussion
The antimicrobial and antifungal effects of the essential oils
and specific activity of plants provided from spontaneous
flora have been noted in numerous studies to date
(Hammer et al., 1998; Giordani et al., 2004; Donaldson et
al., 2005; Cavaleiro et al., 2006; Neves et al. 2009; Baykan
Erel et al., 2012).
From the numerous compounds found in these oils,
with certain studied antifungal activity, eugenol (4-allyl-2methoxyphenol) is a phenolic compound present in many
plants with proven healing bioabilities (Tan et al., 1998;
Hayat et al., 2009; Baykan Erel et al., 2012).
Knowing that candidiasis is a current topic in medicine
(C. albicans being able to show an important deleterious
activity, often followed by relapse), a great number of
active structures were tested and are still being testing
(including the natural compounds here), proving the
importance of this fungal disease. Following our previous
studies concerning microbiological and GC/MS analysis
of plant compositions from Artemisia spp., it emerged that
eugenol is a potent antifungal biocompound and thus an
ideal candidate for further testing to develop novel antiCandida phytotherapeutic means (Obiștioiu et al., 2014).
Following the experimental infection with C. albicans and
after the therapy, the results showed that eugenol was highly
effective in the treatment of genital candidiasis, probably
due to its antioxidant/prooxidant activities. According
to our results about eugenol activity, we agree with the
findings of Özkan and Erdoğan (2013), who demonstrated
that this natural active substance can exhibit membrane and
DNA protective/damaging effects changing in a manner
dependent upon concentration, cell type, and time.
Our experimental findings revealed that, in female
rat genital infection with candidiasis, the organs were
affected in the following order: liver, kidneys, spleen, and
ovaries, demonstrating the erratic development of this
fungal disease. We also observed that, compared to the

placebo group, in the case of groups treated with eugenol
or nystatin, the alterations were much less discernible.
The exception was the liver degeneration, but this was
attributed to the immunosuppressive drugs and not to the
Candida infection.
In this respect, eugenol, an essential oil component
in plants, has been demonstrated to possess dual activity,
antibacterial and/or antifungal, but also a protective one,
especially of the liver, where its activity synergizes with
the hepatic regeneration, a fact proven by some important
studies. For example, the antiperoxidative activity of
eugenol was proven by Nagababu and Lakshmaiah (1992,
1994), who ascertained that incubation of mitochondria
with eugenol resulted in the uptake of significant quantities
of eugenol, which inhibited subsequent lipid peroxidation
by acting as a chain-breaking antioxidant.
In another study, Nagababu et al. (2010), after liver
damage was induced by administration of CCl4 in rats,
proved that eugenol’s inhibitory activity was about fivefold higher than that observed for α-tocopherol and
about ten-fold less than that observed for BHT. Eugenol
also significantly inhibited the rise in SGOT activity and
cell necrosis. The protective action of eugenol has been
ascertained to be due to interception of secondary radicals
derived from ER lipids rather than interference with
primary radicals of CCl4 (respectively: CCl3/CCl3OO).
The efficiency in experimental genital candidiasis
showed by eugenol allows us to consider it as a potent
antifungal agent for candidiasis, with an activity comparable
to that of nystatin. The cytohistological alterations
observed by us in the immunosuppressed infected rats
that were treated with placebo were the most apparent.
We consider that eugenol, as a natural compound, has the
advantage of volatile molecules that can penetrate areas
inaccessible to other antifungal substances also having a
low toxicity.
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